A
Alcista
Alcista · 25%ACAD
$26.83
Precio del escenario
$19.730
-0.564 (-2.86%)Al cierre
Loading chart…
- Máximo
- 20.245
- Apertura
- 20.220
- Precio medio ponderado por volumen
- 19.85
- Volumen
- 1.07M
- Capitalización
- 2.70B
- Mínimo
- 19.577
- Importe
- 21.16M
- EV/EBITDA, TTM
- 16.98
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Análisis de IA of Acadia Pharmaceuticals Inc. (ACAD)
MantenerCurrently, ACADIA Pharmaceuticals Inc is not a strong buy. The stock is trading at $19.73, which is significantly lower than the average analyst price target of $34, indicating potential upside. However, the stock's RSI is at 44.37, suggesting it is nearing oversold territory but not yet a strong buy signal. The recent negative news regarding the RADIANT trial, which missed its primary endpoint, has led to a 24.95% year-to-date decline, posing a significant risk to recovery.
Recomendaciones de analistas (10)
+57.98% de potencial alcista
Comprar
8 Comprar
2 Mantener
0 Vender
Actual: 19.73
Mínimo
23.00
Promedio
31.17
Máximo
40.00
RBC Capital
Superar al mercado
$36
2026-10-08
RBC Capital
2026-10-08
Precio objetivo
$36
Superar al mercado
H.C. Wainwright
Comprar
$33
2026-09-25
H.C. Wainwright
2026-09-25
Precio objetivo
$33
Comprar
Needham
Comprar
$35
2026-09-25
Needham
2026-09-25
Precio objetivo
$35
Comprar
Deutsche Bank
Comprar
$31
2026-09-25
Deutsche Bank
2026-09-25
Precio objetivo
$31
Comprar
BMO Capital
Superar al mercado
$34
2026-09-25
BMO Capital
2026-09-25
Precio objetivo
$34
Superar al mercado
Métricas de valoración
El PER previsto actual de Acadia Pharmaceuticals Inc. (ACAD) es 25.19, frente a su media de 5 años de 6.42.
Escenarios de precio de Alphio AI para ACAD
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ACAD en cartera
Cronología de eventos
Noticias
7.510-21NewsfilterBrain Cancer Treatment Market Shows Promising Growth Potential
6.009-25stocktwitsAnalysts Lower Price Targets for Acadia Pharmaceuticals
2.009-24stocktwitsAcadia Pharmaceuticals Faces Stock Plunge After Remlifanserin Trial Misses Primary Endpoint
8.509-24NewsfilterAcadia Pharmaceuticals Advances Alzheimer’s Drug Development
9.508-31Yahoo FinanceAcadeMedia Reports Strong Q4 Earnings with Record Sales Growth
Preguntas frecuentes sobre ACAD, respondidas por Alphio AI
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, ACADIA Pharmaceuticals Inc is not a strong buy. The stock is trading at $19.73, which is significantly lower than the average analyst price target of $34, indicating potential upside. However, the stock's RSI is at 44.37, suggesting it is nearing oversold territory but not yet a strong buy signal. The recent negative news regarding the RADIANT trial, which missed its primary endpoint, has led to a 24.95% year-to-date decline, posing a significant risk to recovery.
10 analysts cover ACAD: 8 rate it Buy, 2 Hold and 0 Sell. The average price target is 31.17.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.